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Abstract 
Objectives 
The number of geriatric patients with esophageal cancer has been increasing. Geriatric 
syndromes such as sarcopenia might adversely affect postoperative recovery. The aim of this study was to 
evaluate the relationships between sarcopenia and postoperative complications, and the associations 
between sarcopenia and perioperative functional changes in esophageal cancer patients following 
esophagectomy.  
Materials and Methods 
Participants comprised 104 patients who underwent esophagectomy from July 2011 to April 
2015. Preoperative sarcopenia was diagnosed by the presence of low muscle mass and low physical 
functions according to Asian Working Group for Sarcopenia criteria. Low physical function was defined 
by loss of grip strength and/or slow walking speed. Postoperative pulmonary, cardiac, infection, and 
surgical complications were extracted. Perioperative functional changes were calculated (value at 
postoperative day 30 – value before surgery). For statistical analyses, both uni- and multivariate logistic 
regression analyses were performed. 
Results 
Twenty-nine patients (27.9 %) were diagnosed with sarcopenia. The incidence of 
postoperative pulmonary complications was significantly higher in the sarcopenia group (37.9 %) than in 
the non-sarcopenia group (17.3 %; P=0.04). There was no relationship between sarcopenia and other 
complications or perioperative functional changes. Multivariate analysis identified sarcopenia (odds ratio 
(OR), 3.13; 95% confidence interval (CI), 1.12-8.93) and high Brinkman index (OR, 3.46; 95% CI, 
1.20-11.77) as independent risk factors for the development of pulmonary complications.  
Conclusion 
The assessment of sarcopenia may be useful to predict the postoperative pulmonary 
complications following esophagectomy. On the other hand, sarcopenia does not predict cardiac, infection, 
and surgical complications or perioperative function. 
 
Keywords  
sarcopenia ; postoperat ive pu lmo nar y complicat ions ; esophagectomy; esophagea l  
cancer ; rehabi l it at ion; funct iona l st atus  
  
Introduction 
Esophageal cancer is a highly aggressive malignant tumor, and esophagectomy is associated 
with high morbidity and mortality rates 
1,2
. The proportion of older patients with esophageal cancer has 
been increasing in the United States, Europe, and Japan 
3-5
. The impact of geriatric syndrome on 
esophagectomy is of considerable importance. 
Sarcopenia, characterized by progressive generalized loss of skeletal muscle mass and 
strength with a risk of adverse outcomes such as physical disability, loss of independence and death 
6,7
, is 
a common geriatric syndrome. The European Working Group on Sarcopenia in Older People recommends 
using the presence of both low muscle mass and low muscle function to diagnose sarcopenia 
8
. In the 
previous studies, sarcopenia has been identified as an independent predictor of postoperative pulmonary 
complications following esophagectomy 
9,10
, but the diagnosis of sarcopenia in those studies was made 
based on the presence of low muscle mass alone. Furthermore, no published reports have described the 
effects of preoperative sarcopenia on perioperative functional change. We hypothesized that sarcopenia 
defined by both low muscle mass and low muscle function predicted postoperative complications and 
perioperative functional changes in esophageal cancer patients following esophagectomy. 
The aim of this study was to assess preoperative sarcopenia using both muscle mass and 
function and to evaluate the relationship between sarcopenia and postoperative outcomes such as 
postoperative complications and perioperative functional change in patients with esophageal cancer who 
underwent esophagectomy. 
 
Materials and methods 
Participants 
The present study was a retrospective cohort study. This study was conducted between July 
2011 and April 2015 at the single university hospital located in the urban area. Patients with esophageal 
cancer were eligible if they were scheduled to undergo definitive esophagectomy. Patients were excluded 
if they had a recurrent cancer or declined to consent. The study was approved by the ethics committee of 
Kobe University Graduate School Health Science (approval number 112) and registered with the 
University Hospital Medical Information Network. This study was performed in accordance with the 
ethical standards established in the 1964 Declaration of Helsinki and later amendments. 
Measurements 
Preoperative laboratory data and treatment information were collected from the medical 
records of patients. Laboratory data included predicted vital capacity (VC), forced expiratory volume in 1 
s (FEV1.0) as a percentage of forced VC, C-reactive protein (CRP) and serum albumin. Treatment 
information was as follows: preoperative clinical stage, comorbidity, smoking history, performance status, 
weight loss over the past 6 months, preoperative treatment, operative time, blood loss, duration of 
inhibited oral intake, and duration of hospitalization after surgery. Clinical staging was based on the TNM 
classification (6th edition) 
11
 defined by the Union for International Cancer Control. Smoking history was 
assessed using the Brinkman index defined as numbers of cigarette smoked per day times smoking years. 
Performance status was defined based on the Eastern Cooperative Oncology Group Performance Status. 
Neoadjuvant chemotherapy with cisplatin plus 5-fluorouracil was provided as preoperative treatment. We 
calculated the Geriatric Nutritional Risk Index (GNRI) 
12
 using preoperative serum albumin and body 
weight. 
Body composition, muscle strength, mobility, fatigue and health-related quality of life 
(HRQoL) were assessed before esophagectomy and on postoperative day (POD) 30. We prepared the 
assessment manual to reduce potential measurement bias. Body composition was assessed using 
multifrequency bioelectrical impedance with eight electrodes (DF-860; Yamato, Hyogo, Japan). With this 
method, body weight, lean body mass and skeletal muscle mass were measured. Grip strength was 
measured using a handheld dynamometer (GRIP-D; Takei Ltd., Niigata, Japan) in accordance with the 
reliable methods reported previously 
13
. Mobility was measured using the Short Physical Performance 
Battery (SPPB) 
14
, assessing standing balance, walking speed, and ability to rise from a chair (total score, 
0-12; higher score suggesting better mobility). Fatigue and HRQoL were measured using the Functional 
Assessment of Chronic Illness Therapy: Fatigue (FACIT-F) 
15
 and the Functional Assessment of Cancer 
Therapy - General (FACT-G) 
16
, respectively. The FACT-G total score for the Physical, Social/Family, 
Emotional, and Functional subscales was used. Higher scores on the FACIT-F and FACT-G represent less 
fatigue and better quality of life, respectively. 
Definition of Sarcopenia 
Sarcopenia was defined as low muscle mass plus low muscle strength and/or low physical 
performance according to the Asian consensus definition 
17
. Low muscle mass was defined by 
appendicular skeletal muscle mass divided by squared height of <7.0 kg/m
2
 for men and <5.7 kg/m
2
 for 
women. Low muscle strength was defined by handgrip strength of <26 kg for men and <18 kg for women. 
Low physical performance was defined by gait speed of <0.8 m/s. In the non-sarcopenia group, patients 
with low muscle mass were described as showing presarcopenia. In the sarcopenia group, patients were 
described as showing severe sarcopenia when all three criteria were met. 
 
Evaluation of Outcomes 
Data on postoperative complications were collected from the medical records of patients. 
Postoperative complications were defined according to the Society of Thoracic Surgeons General 
Thoracic Surgery Database guidelines 
18
 and the Clavien-Dindo classification 
19
. Pulmonary complication 
was defined as the presence of any of the following postoperative conditions within 30 days after surgery: 
initial ventilatory support for >48 h, reintubation for respiratory failure or pneumonia. Any cardiac 
disease defined as Clavien-Dindo grade >Ⅱ was chosen as cardiovascular complications. Infection 
complication was defined as the presence of wound infection, abscess, sepsis or other infections requiring 
antibiotics within 30 days after surgery. Surgical complication was defined as the presence of rebleeding, 
anastomotic leakage or chylothorax within 30 days after surgery. 
Statistical Analysis 
Test of normality was conducted using Shapiro-Wilk test. Relationships between 
patient/treatment characteristics and the presence of sarcopenia were compared using Student’s t-test for 
normalized variables, Mann Whitney U test for non-normalized values, and Fisher’s exact test for 
categorical values. Univariate logistic regression analyses were performed to assess the association 
between various prognostic predictors that have been reported previously 
20,21
 and postoperative 
pulmonary complications. Factors in univariate analysis showing values of a P < 0.10 were entered 
simultaneously into a multivariate logistic regression model. Changes in measurement values were 
calculated (value at POD30 – value before surgery) and group differences in measurement change were 
analyzed using multiple linear regression analysis. The following patients were excluded from the 
statistical analysis due to the missing postoperative values: 30 patients for lean body mass, 29 for grip 
strength, 35 for SPPB, 39 for fatigue, and 40 for HRQoL. To control for confounding factors, the baseline 
value, age, gender, and GNRI were entered simultaneously into the regression model. GNRI was selected 
because preoperative nutritional status could affect recovery after elective surgery 
22
. Sensitivity analysis 
was performed to evaluate the effect of missing sarcopenia diagnosis on the association between 
sarcopenia and postoperative complications. Multivariate logistic regression analyses were performed 
when patients without sarcopenia diagnosis were included in either sarcopenia or non-sarcopenia group. A 
value of P < 0.05 was considered statistically significant. All statistical analyses were performed using the 
JMP 8.0.1 software (SAS Institute Japan, Tokyo, Japan). 
 
Results 
A total of 104 of the 131 eligible patients were enrolled in the study. Postoperative follow-up 
was performed until discharge. The reasons for exclusion and the number of patients available for 
analyses are shown in Figure 1. Sixteen patients excluded from analysis due to the missing preoperative 
assessment were devoid of the opportunities to be assessed sarcopenia before esophagectomy. Of the 
analysis population, 29 patients (27.9%) were classified into the sarcopenia group and 75 patients 
(72.1%) into the non-sarcopenia group. All patients in the non-sarcopenia group showed presarcopenia. 
Nine patients in the sarcopenia group showed severe sarcopenia. 
Clinical characteristics of analysis population are summarized in Table 1. Patients in the 
sarcopenia group were significantly older and diagnosed with more advanced clinical stage compared to 
the non-sarcopenia group. In addition, sarcopenia patients had significantly higher CRP levels, lower 
serum albumin levels, and greater weight loss over the past 6 months than non-sarcopenia patients. Both 
preoperative respiratory function and nutritional status were poorer in the sarcopenia group than in the 
non-sarcopenia group, but presence of comorbidities, performance status, and preoperative treatment 
were comparable. Although the rate of received neoadjuvant chemotherapy (43.8 %) was significantly 
lower in the 16 patients excluded from analysis due to the missing preoperative assessment than the 
others, the other characteristics including operative variables and surgical outcomes had no significant 
difference. 
Pulmonary complications occurred in 24 patients (23.1 %, pneumonia = 24, reintubation = 9). 
Postoperative pulmonary complications occurred significantly more frequently in the sarcopenia group 
(37.9 %) than in the non-sarcopenia group (17.3 %) (Table 2). Rates of postoperative cardiac, infection, 
and surgical complications did not differ significantly between the groups. 
Univariate logistic regression analysis revealed sarcopenia and high Brinkman index as 
factors significantly associated with postoperative pulmonary complications (Table 3). Moreover, 
multivariate logistic regression analysis showed sarcopenia and high Brinkman index were independent 
risk factors for pulmonary complications (Table 3). The rate of postoperative pulmonary complications 
was 18.8 % in patients without sarcopenia diagnosis. In sensitivity analysis, sarcopenia was an 
independent risk factor for pulmonary complications (ORs, 3.04; 95% CI, 1.12 – 8.23) when all of the 
patients without sarcopenia diagnosis were included in the non-sarcopenia group. On the other hand, 
sarcopenia was not an independent risk factor (ORs, 2.15; 95% CI, 0.87 – 5.38) when all of the patients 
without sarcopenia diagnosis were included in the sarcopenia group. 
The relationship between sarcopenia and perioperative functional change are shown in Table 
4. In the baseline comparison, body weight, lean body mass, grip strength, and SPPB were significantly 
lower in the sarcopenia group than in the non-sarcopenia group (p < 0.001). In comparison of change at 
POD30, perioperative decrease in body weight was significantly less in the sarcopenia group (p = 0.004), 
but sarcopenia patients were significantly more likely to experience increased fatigue (p = 0.002). In 
multiple linear regression analysis adjusted for baseline value, age, gender, and GNRI (shown in Table 4), 
no significant difference in measurement change was evident between groups. 
 
Discussion 
The aim of this study was to assess sarcopenia using both muscle mass and function, and to 
evaluate relationships between sarcopenia and postoperative complications and between sarcopenia and 
perioperative functional changes in patients with esophageal cancer who underwent esophagectomy. The 
prevalence of sarcopenia at the baseline was 27.9 %. Sarcopenia was associated with the development of 
postoperative pulmonary complications. There was no relationship between sarcopenia and other 
complications or perioperative functional changes. 
The prevalence of sarcopenia (27.9 %) was lower than that shown in previous reports (44.2 - 
74.9 %) 
9,10
, of which sarcopenia was diagnosed by the presence of low muscle mass alone based on their 
own cut-off values. All patients in the non-sarcopenia group in the present study had presarcopenia, 
although all these patients were diagnosed as sarcopenia based on the presence of low muscle mass alone. 
Patients with esophageal cancer frequently experience dysphagia, and the weight loss results in decreased 
muscle mass 
23
. Assessing sarcopenia using the presence of low muscle mass alone may overestimate 
sarcopenia and decrease sensitivity in esophageal cancer. The most common definition of sarcopenia is 
defined by both low muscle mass and low muscle function based on consensus values. Our findings may 
be more realistic and give the strong support to the relationship between sarcopenia and postoperative 
pulmonary complications. A previous study showed that grip strength offered an effective predictor of 
complications and mortality after elective esophagectomy 
24
, and that walking speed predicted risk of 
mortality 
25
. Because tests for grip strength and walking speed are inexpensive and predictive of high-risk 
patients, not only muscle mass but also muscle function may be worth assessing before esophagectomy. 
In our study, patients with sarcopenia showed more advanced clinical stage, higher CRP 
levels, more weight loss in the past 6 months and the worse preoperative nutritional status. The etiology 
of sarcopenia is considered multi-factorial, involving issues such as the physiological aging process, 
physical inactivity, inadequate nutrition, and comorbid diseases 
8
. Our results suggest that sarcopenia in 
esophageal cancer reflects tumor-related symptoms such as chronic inflammation, weight loss, and 
malnutrition and that sarcopenia may be an indicator of general condition in patients who undergo 
definitive esophagectomy. 
It may be clinically plausible that sarcopenia affects the risk of developing postoperative 
pulmonary complications. Sarcopenia patients showed that the impairment of pulmonary function as the 
result of weakened respiratory muscles could lead to insufficient cough, atelectasis, and pneumonia 
26,27
. 
A previous study reported that preoperative inspiratory muscle training was effective in reducing the 
development of postoperative pulmonary complications 
28
. Preoperative interventions, such as exercise 
and nutritional support, might improve muscle function in sarcopenia patients. 
Associations between sarcopenia and cardiac, infection, or surgical complications are unclear 
because few findings have been reported. Our findings are in agreement with those of the previous report 
10
 and suggest that sarcopenia may not predict other complications unlike pulmonary complications. 
Further research is needed to determine the associations between sarcopenia and cardiac, infection, or 
surgical complications. 
We expected that sarcopenia patients would lack the physiological reserve to compensate for 
surgical stress, but our results showed that sarcopenia was not associated with short-term functional 
change. In fact, it has been reported that sarcopenia was associated with an increased inflammatory 
response to surgery 
29
. However, that may not result in short-term functional change after esophagectomy. 
Several limitations of this study should be acknowledged. First, a large-scale, 
multi-institutional study is needed to validate our findings, because our study was the small number of 
patients included and the single institutional study. Second, the results of this study may not be applicable 
to those who are not Asian people because of the difference in definition of sarcopenia. Third, as shown 
in sensitivity analysis, the missing data likely inflated the observed association between sarcopenia and 
pulmonary complications. 
In conclusion, sarcopenia as defined by muscle mass and function may offer a predictor of 
postoperative pulmonary complications after esophagectomy. Sarcopenia should be defined according to 
not only the presence of low muscle mass, but also low muscle strength and physical performance. 
Further analysis is needed to clarify whether preoperative exercise intervention can improve sarcopenia 
and reduce postoperative pulmonary complications. 
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Figure 1. Flow diagram of participants 
  
Table 1. Baseline characteristics 
Variables Sarcopenia (n = 
29) 
Non-sarcopenia (n = 
75) 
P value 
Age (years old) 
Gender (male / female) 
Body mass index (kg/m
2
) 
Brinkman index 
CRP (mg/dl) 
Serum albumin (g/dl) 
Preoperative respiratory function 
Predicted VC (%) 
FEV1.0% 
GNRI 
Comorbidity, n (%) 
Hypertension 
Diabetes mellitus 
Chronic pulmonary disease 
Circulatory disease 
Performance status (0/1/2) 
Weight loss past 6 months (%) 
Histology, n (%) 
AC/SCC/MM 
Clinical stage (1/2/3/4) 
Preoperative treatment, n (%) 
Neoadjuvant chemotherapy 
69 (66 – 76) 
22/7 
19.3 ± 2.6 
700 (0 – 1000) 
0.20 (0.10 – 0.44) 
3.8 (3.3 – 4.1) 
  
93.2 ± 14.2 
70.4 ± 12.7 
91.2 (82.8 – 98.8) 
  
8 (27.6 %) 
3 (10.3 %) 
11 (37.9 %) 
5 (17.2 %) 
26/2/1 
8.8 ± 9.0 
 
1/28/0 
4/6/16/3 
 
24 (82.8 %) 
64 (61 – 71) 
66/9 
21.7 ± 2.8 
565 (158 – 820) 
0.10 (0.10 – 0.18) 
4.0 (3.8 – 4.3) 
  
100.1 ± 12.0 
74.1 ± 9.5 
101.3 (95.0 – 103.9) 
  
34 (45.3 %) 
7 (9.3 %) 
20 (26.7 %) 
4 (5.3 %) 
70/3/2 
3.3 ± 5.9 
 
4/70/1 
16/32/26/1 
 
57 (76.0 %) 
0.004 
0.14 
< 0.001 
0.78 
0.01 
0.003 
  
0.02 
0.12 
< 0.001 
  
0.12 
1.00 
0.34 
0.11 
0.69 
0.001 
 
1.00 
0.02 
 
0.60 
Data are expressed as mean ± standard deviation or median (interquartile ranges) 
CRP, C-reactive protein; VC, vital capacity; FEV, forced expiratory volume; GNRI, Geriatric Nutritional 
Risk Index; AC, adenocarcinoma; SCC, squamous cell carcinoma; MM, malignant melanoma. 
Table 2. Operative variables and surgical outcomes, stratified by sarcopenia status 
Variables Sarcopenia (n = 
29) 
Non-sarcopenia (n = 
75) 
P value 
Operative time (min) 
Blood loss 
*
 (ml/kg) 
Postoperative complication, n (%) 
Pulmonary 
Cardiovascular 
Infection 
Surgical 
Duration of inhibited oral intake (days) 
Hospitalization after surgery (days) 
711 (628 – 773) 
10.9 (8.5 – 14.9) 
  
11 (37.9 %) 
9 (31.0 %) 
5 (17.2 %) 
6 (20.7 %) 
9 (7 – 19) 
53 (32 – 80) 
715 (657 – 786) 
5.6 (3.3 – 8.3) 
  
13 (17.3 %) 
17 (22.7 %) 
10 (13.3 %) 
9 (12.0 %) 
9 (7 - 14) 
28 (23 – 41) 
0.50 
< 0.001 
 
0.04 
0.45 
0.76 
0.35 
0.23 
< 0.001 
Data are expressed as median (interquartile ranges) 
* volume of bleeding / body weight 
 
Table 3. Risk factors for postoperative pulmonary complications 
Variables Univariate logistic regression 
(N=104) 
Multivariate logistic 
regression (N=104) 
OR 95% CI P 
value 
OR 95% CI P value 
Age (years old) 
> 70 
Gender 
Male 
Body mass index (kg/m
2
) 
< 18.0 
Clinical stage 
> 2 
Brinkman index 
≥ 400 
Predicted VC (%) 
< 80 
FEV1.0% 
< 70 
Albumin (g/dl) 
< 3.5 
Chronic pulmonary disease 
Yes 
Operative time (min) 
> 540 
Blood loss 
*
 (ml/kg) 
> 20 
Sarcopenia 
Yes 
 
1.76 
 
2.33 
 
1.49 
 
1.35 
 
3.09 
 
2.92 
 
1.61 
 
2.08 
 
1.24 
 
0.14 
 
1.73 
 
2.91 
 
0.69 – 4.47 
 
0.59 – 15.60 
 
0.43 – 4.59 
 
0.54 – 3.38 
 
1.04 – 9.14 
 
0.67 – 12.06 
 
0.61 – 4.12 
 
0.58 – 6.78 
 
0.45 – 3.24 
 
0.01 – 1.52 
 
0.23 – 9.47 
 
1.12 – 7.61 
 
0.23 
 
0.29 
 
0.50 
 
0.52 
 
0.04 
 
0.13 
 
0.32 
 
0.23 
 
0.67 
 
0.11 
 
0.54 
 
0.03 
 
 
 
 
 
 
 
 
 
3.46 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.13 
 
 
 
 
 
 
 
 
 
1.20 – 11.77 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.12 – 8.93 
 
 
 
 
 
 
 
 
 
0.03 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.03 
OR, odds ratio; CI, confidence interval; VC, vital capacity; FEV1.0, forced expiratory volume in 1 s 
* volume of bleeding / body weight 
  
Table 4. Relationship between sarcopenia and perioperative functional changes 
Measure Sarcopenia (n = 29) Non-sarcopenia (n = 75) Adjusted group 
difference in 
mean changes * 
(95%CI) 
Adjusted 
p value Baseline 
Change at 
POD30 
Baseline 
Change at 
POD30 
Body weight (kg) 
Lean body mass (kg) 
Grip strength (kg) 
SPPB 
FACIT-F 
FACT-G 
51.1 ± 8.9 
38.0 ± 7.5 
21.7 ± 9.4 
10.5 ± 2.2 
39.3 ± 6.9 
74.9 ± 13.1 
-2.7 ± 2.3 
-2.6 ± 2.6 
-1.5 ± 3.9 
-0.5 ± 1.6 
-6.4 ± 13.2 
-8.1 ± 8.0 
59.7 ± 10.1 
45.8 ± 7.4 
31.8 ± 5.9 
11.8 ± 0.5 
35.6 ± 11.4 
74.4 ± 14.1 
-4.2 ± 1.8 
-3.4 ± 1.8 
-1.8 ± 2.8 
-0.3 ± 0.8 
6.5 ± 13.3 
-8.8 ± 12.0 
0.4 (-0.6 – 1.4) 
0.4 (-0.7 – 1.6) 
0.9 (-1.1 – 2.9) 
-0.2 (-0.9 – 0.6) 
-6.1 (-13.0 – 0.9) 
0.01 (-7.0 – 7.0) 
0.41 
0.44 
0.38 
0.68 
0.09 
0.99 
CI, confidence interval; POD, postoperative day; SPPB, short physical performance battery; FACIT-F, 
Functional Assessment of Chronic Illness Therapy – Fatigue Scale; FACT-G, Functional Assessment of 
Cancer Therapy – General. 
*
 Adjusted for baseline value, age, gender, and Geriatric Nutritional Risk Index. 
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